Physician profile
Carol E Schmidt
NPI 1609878883
$9,180.78
in general payments reported to CMS, 2019-2025
29 companies · $1,721 in 2025
The $1,721 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $785 · 2020: $606 · 2021: $1,603 · 2022: $1,270 · 2023: $1,175 · 2024: $2,022 · 2025: $1,721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,917.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,917.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $4,209.57 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $868.97 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $778.78 | 2021-2025 | Mounjaro |
| Amgen INC. | $710.36 | 2019-2025 | Otezla, Repatha, Evenity |
| Amarin Pharma, INC. | $414.16 | 2019-2021 | |
| Glaxosmithkline, LLC. | $296.05 | 2019-2024 | Arexvy, Shingrix |
| Abbott Laboratories | $270.40 | 2021-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $207.70 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $193.51 | 2023-2024 | Veozah, Myrbetriq |
| Idorsia Pharmaceuticals US INC | $148.44 | 2022 | |
| Pfizer INC. | $139.26 | 2025 | |
| Corcept Therapeutics | $132.97 | 2025 | Korlym |
| Radius Health, INC. | $124.23 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $117.26 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $115.25 | 2019-2025 | Ajovy |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $79.94 | 2022-2025 | |
| Sanofi Pasteur INC. | $70.34 | 2021-2023 | |
| Gilead Sciences, INC. | $43.59 | 2020-2021 | |
| Esperion Therapeutics, INC. | $42.90 | 2021 | |
| Viiv Healthcare Company | $40.69 | 2024 | Apretude |
| Biohaven Pharmaceutical Holding Company Ltd. | $34.38 | 2022 | |
| Phadia US INC. | $23.86 | 2024 | Immunocap |
| Avvisto Therapeutics, LLC | $22.65 | 2025 | Cycloset |
| Abbvie INC. | $18.03 | 2024 | |
| Almatica Pharma LLC | $17.28 | 2022 | |
| Grifols USA, LLC | $16.98 | 2019 | |
| Seqirus USA INC | $16.40 | 2019 | |
| Shire North American Group INC | $13.78 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.